Convatec showcases its strongest wound care innovation pipeline ever at EWMA

Convatec’s Advanced Wound Care business to showcase breakthrough solutions in exudate management, hard-to-heal wounds, and clinical evidence supporting next-generation dressing technologies
Convatec-sponsored Innovation Forum will feature events, networking and partnership opportunities for start-ups

London, UK, 18 March 2025 – Convatec, a leading medical products and technologies company focused on solutions for the management of chronic conditions, will showcase its latest innovations in advanced wound care solutions at the European Wound Management Association (EWMA) 2025 conference, in Barcelona, Spain from 26-28 March 2025. 

Convatec’s significant launches for Advanced Wound Care lead the company’s strongest innovation pipeline in its history. At EWMA 2025, Convatec will highlight key findings and the latest developments designed to deliver better healing outcomes, reduce treatment burden and enhance the patients’ quality of life, including:

ConvaFoam^TM: Our next-generation advanced multi-layered foam dressing which offers excellent exudate management in acute wounds and strong outcomes in wound size reduction and closure in hard-to-heal wounds¹. Convatec will host a symposium to explore the role of next-generation foam dressings in improving patient care.

Superior healing outcomes in hard-to-heal venous leg ulcers: Presentation of published results from a multinational randomised controlled trial (RCT) demonstrating superior outcomes at 12 weeks with an enhanced silver-containing dressing (Aquacel^® Ag+ Extra /Aquacel^® Ag Advantage) versus the standard of care. The study has now been peer-reviewed in the Journal of Wound Care^2.

Impact of Wound Hygiene protocol in hard-to-heal wounds: Convatec will host a second symposium to discuss the role of the Wound Hygiene protocol and how small changes can make a significant difference in wound closure, supported by clinical research. The Wound Hygiene protocol recently won the Innovation in Chronic Wound Healing category at the Journal of Wound Care Awards 2025.

Innovation forum and competition
As part of our commitment to pioneering innovation, Convatec is sponsoring the EWMA innovation forum and innovation competition which supports startups within the wound healing sector (including therapeutics, MedTech, diagnostics, AI, and service providers).

The competition offers €10,000 for the winner with the potential to dramatically increase the quality and effectiveness of wound care for patients through innovative solutions. The winner will be announced next week during the event. 

The forum will host a series of events and speakers which aims to unlock collaboration and accelerate market entry for European startups. In addition it will facilitate opportunities for strategic investment, partnerships and joint development for the benefit of HCPs and patients. For more information on the full programme of events, see the link here. 

David Shepherd, President & Chief Operating Officer, Advanced Wound Care, Convatec, said: “We’re passionate about supporting patients to manage the burden of wound care, and EWMA is a great platform to showcase our latest advancements and innovation in this area. Backed by strong clinical evidence, our products can demonstrate a transformative effect on patient outcomes and we’re consistently pushing science and care forward.”

Notes to editors

For more information visit the EWMA website https://ewma.org/2025conference/

Contact
Investor Relations: IR@convatec.com   
Media: MediaRelations@convatec.com

About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide our products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Convatec’s revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com